# A Clinical Study to Evaluate Single-agent Therapy of BR113 for Injection in Patients With Advanced Solid Tumors

> **NCT07753590** · PHASE1 · NOT_YET_RECRUITING · sponsor: **BioRay Pharmaceutical Co., Ltd.** · enrollment: 258 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** BR113 for injection

## Key facts

- **NCT ID:** NCT07753590
- **Lead sponsor:** BioRay Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2030-02
- **Final completion:** 2030-12
- **Target enrollment:** 258 (ESTIMATED)
- **Last updated:** 2026-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07753590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07753590, "A Clinical Study to Evaluate Single-agent Therapy of BR113 for Injection in Patients With Advanced Solid Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07753590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*